Overall, these results demonstrated that H2AX, Ser345-Chk1 and p21 phosphorylation levels, as well as ROS generation induced by axitinib alone or in combination with bortezomib, promoted the sensitivity of glioma cells, and overcame the resistance, through the activation of different cell death outcomes. This evidence concerns the gene CDKN1A and central nervous system cancer.